Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.47 |
| ▸ | HPGDS | O60760 | 4/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293915 | 0.82 | F2 (0.48) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8294505 | 0.81 | F2 (0.63) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8293906 | 0.81 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14508580 | 0.81 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28443943 | 0.70 | ELANE (0.47) | ELANE | |
| SCHEMBL28443945 | 0.70 | ELANE (0.47) | ELANE | |
| SCHEMBL989218 | 0.67 | EPHX1 (0.53) | HPGDSELANE | |
| SCHEMBL13711063 | 0.67 | EPHX1 (0.53) | HPGDSELANE | |
| SCHEMBL3596182 | 0.67 | EPHX1 (0.53) | HPGDSELANE | |
| Hydrochloric Acid SCHEMBL6895586 | 0.66 | EPHX1 (0.51) | HPGDSELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | F2 1/4885PRSS1 67/4885HPGDS 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.